Neurocrine Biosciences, Inc.

Good day everyone and welcome to today's Neurocrines Biosciences reports third quarter results. At this time all participants are in a listen only mode. Later you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star 1 on your touch tone phone. You may withdraw yourself from the queue by pressing the pound key. Please note that this call may be recorded and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Todd Tushla, Vice President of Investor Relations. Please go ahead.

Thank you, operator, and good morning to everyone. Welcome to our third quarter of 2022 earnings call. On today's call, we have Kevin Gorman, our Chief Executive Officer, Matt Abernathy, our Chief Financial Officer, Irie Roberts, our Chief Medical Officer, Eric Benevich, our Chief Commercial Officer, and Kyle Gano, our Chief Business Development and Strategy Officer. During our call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. We will go to Q&A after prepared remarks, and we'll do our best to get to everyone's questions. With that, I'll hand the call to Kevin.

Thanks, Todd. Good morning, everyone. Well, another very nice quarter of aggressive sales, and this sets us up well for continued growth in Q4. I'm pleased to see that the investments that we have been making in Ingresa this year and last year are starting to show results, and it is our expectation we will continue to increase our ability to treat TD patients so they don't suffer needlessly. In addition, we are seeing clinical development activities with valbenazine are showing good progress. This is most clearly demonstrated by our filing of the SNDA for the treatment of Korean Huntington's disease. We continue to build and progress our pipeline. But I'm going to stop now and let Eric and Irie provide more detail on commercial and clinical and then move quickly to your questions. Let's start with Matt. Good morning, everyone.